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Abstract
For more than a century oxygen has been known to be one of the most powerful radiosensitizers. However, despite
decades of preclinical and clinical research aimed at overcoming tumor hypoxia, little clinical progress has been made so far.
Ionizing radiation damages DNA through generation of free radicals. In the presence of oxygen these lesions are chemically
modified, and thus harder to repair while hypoxia protects cells from radiation (Oxygen enhancement ratio (OER)). Breast
cancer stem cells (BSCSs) are protected from radiation by high levels of free radical scavengers even in the presence of
oxygen. This led us to hypothesize that BCSCs exhibit an OER of 1. Using four established breast cancer cell lines (MCF-7,
T47D, MDA-MB-231, SUM159PT) and primary breast cancer samples, we determined the number of BCSCs using cancer
stem cell markers (ALDH1, low proteasome activity), compared radiation clonogenic survival and mammosphere formation
under normoxic and hypoxic conditions, and correlated these results to the expression levels of key members of the free
radical scavenging systems. The number of BCSCs increased with increased aggressiveness of the cancer. This correlated
with increased radioresistance (SF8Gy), and decreasing OERs. When cultured as mammospheres, breast cancer cell lines and
primary samples were highly radioresistant and not further protected by hypoxia (OER,1). We conclude that because
BCSCs are protected from radiation through high expression levels of free radical scavengers, hypoxia does not lead to
additional radioprotection of BCSCs.
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Introduction
In 1909 Gottwald Schwarz reported that a reduction in blood
flow and thus oxygen supply protected the human skin from X-
rays [1]. Since then a plethora of studies confirmed Schwarz’s
observation in different species and tissues. Today, oxygen is
recognized to be one of the most powerful radiation sensitizers.
The ratio of the radiation doses required for equal cell killing
under hypoxic and normoxic conditions is called oxygen
enhancement ration (OER) and is for most cells and X-rays in
the range of 2–3. A widely accepted mechanism behind the
sensitizing effects of oxygen is that DNA lesions produced in the
presence of oxygen result in chemically modified DNA strands that
cannot easily be repaired.
Cancers are known for their irregular vasculature that fails to
provide sufficient oxygen supply to parts of a tumor [2], thus
leading to chronic hypoxia in a subpopulation of tumor cells
distant from capillaries. In addition, high intra-tumoral pressure
and the irregular structure of the tumor blood vessels [2] hinders
regular blood flow and primes the tumor vasculature to frequent
occlusions by micro-thrombosis and subsequent recanalization,
thereby causing changes between acute hypoxia and reoxygena-
tion of those cancer cells that depend on the affected capillaries
[3]. A general assumption is that during fractionated radiation
treatment, normoxic cells are preferentially killed and portions of
the surviving chronically hypoxic parts of the tumor are
vascularized, oxygenated and thus, sensitized to subsequent
fractions of radiation [4]. In addition, fractionated radiation
normalizes the irregular structure of the vascular network inside of
tumors, thereby reducing the frequency of micro-thrombosis and
acute hypoxia [5]. Even though there is some controversy on
which form of hypoxia is more important for treatment outcome,
it is in general widely accepted that the hypoxic fraction of cells
inside a tumor at the time of irradiation determines its curability.
Recent preclinical [6,7] and clinical [8,9] data support that solid
cancers including breast cancers are organized hierarchically with
a small population of cancer stem cells (CSCs), capable of re-
growing the entire tumor while their progeny lack this ability [10].
Furthermore, we and others reported that breast CSCs (BCSCs)
are relatively resistant to ionizing radiation [11,12]. One
mechanism behind this resistance is a drastically reduced amount
of free radicals formed following irradiation, which leads to
reduced numbers of DNA double strand breaks, thus suggesting
the presence of high levels of free radical scavengers in BCSCs
[11]. Based on our observation that BCSCs efficiently scavenge
free radicals generated by radiation we hypothesized that BCSCs
would not be protected by hypoxia to the same extent as their non-
tumorigenic counterparts.
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High numbers of BCSCs correlate with increased
malignancy
We started our study comparing plating efficiencies and the size
of the putative breast cancer stem cell pool in luminal, basal, and
claudin-low breast cancer lines and patient-derived primary breast
cancer samples. Plating efficiency (PE) in clonogenic survival
assays measures the number of CSCs and transiently amplifying
cells. PEs of both luminal lines were low (MCF-7: 5.160.5%;
T47D: 12613%) but PEs increased with increased malignancy in
basal (MDA-MB-231: 56.568.9%), claudin-low cell lines
(67.2613.3%) and primary breast cancer samples from patients
with relapsed breast cancers (BCCL2: 38615.6%; BCCL3:
4367.1%), thus indicating increased numbers of CSCs and
transiently amplifying cells in the more malignant breast cancer
types (Fig. 1).
To assess the size of the BCSC pool more directly we used two
different marker systems: activity of ALDH1 and a system
developed in our laboratory that uses lack of proteasome activity
to identify BCSCs [13,14] and was recently shown to correlate
with early recurrence in early stage breast cancer patients (T1/2,
N0/1) after radiation therapy [15]. Our system relies on
constitutive expression of a fusion protein consisting of the green
fluorescent protein ZsGreen and the C-terminal degron of murine
ornithine decarboxylase. In cells in which the 26S proteasome is
active, the fusion protein is translated and immediately degraded
by the 26 proteasome in an ubiquitin-independent fashion. In cells
that lack proteasome activity or in which the proteasome is
inhibited pharmacologically, the fluorescent fusion protein accu-
mulates and the cells can be identified by fluorescent microscopy
or flow cytometry [13]. The frequency of ZsGreen-cODC
+
BCSCs in the luminal cell lines was 0.1% in MCF-7 and 0.9%
T47D. In contrary, the frequency of ZsGreen-cODC
+ BCSCs in
basal MDA-MB-231 cells was 11-fold higher (1.18%) and 25-fold
higher in the claudin-low SUM159PT cell line (2.46%) (Fig. 2).
Primary patients-derived breast cancer samples do not express
the ZsGreen-cODC reporter and engineering these samples to
stably express the construct would have required weeks in
selections. Since passaging under tissue culture condition carries
the risk of induced changes in the phenotype we used ALDH1
activity as an additional marker system to assess the frequency of
Figure 1. Plating efficiency and percentage of stem cells. (A) Plate efficiency of breast cancer cell lines and patient-derived tumor samples in
clonogenic survival assays under normoxic and hypoxic conditions. (B) Percentage of ZsGreen-cODC
+ BCSCs in established breast cancer cell lines. (C)
Percentage of ALDH
+ cells in established breast cancer cell lines and patient-derived tumor samples.
doi:10.1371/journal.pone.0034545.g001
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trend seen for ZsGreen-cODC
+ cells with increased frequencies of
ALDH
+ cells in more aggressive breast cancers (MCF-7: 0.98%;
T47D: 1.34%; MDA-MB-231: 2.04%; SUM159PT: 8.68%;
BCCL2: 11.1%; BCCL3: 7.17%) (Fig. 3).
Breast cancer cell lines show a broad range of oxygen
enhancement ratios
In order to test our hypothesis we kept cells from four
established breast cancer cell lines, MCF-7, T47D, MDA-MB-
231, and SUM-159PT under acute hypoxic conditions (2 h, 0.1%
O2) or normoxia (atmospheric conditions, 21% O2) and irradiated
cells with 0, 2, 4, 6, 8, or 10 Gy. To assess clonogenic survival, cells
were plated and kept under standard tissue culture conditions for 3
weeks after which the number of colonies formed at each dose
point was counted and normalized to the corresponding un-
irradiated control (Figs. 2, 3, 4C). Since some of the cell lines and
patient-derived samples were extremely radioresistant, we calcu-
lated OERs at a surviving fraction of 0.5. This allowed for better
comparison of the OERs of the different cells. The luminal cell
lines MCF-7 and T47D cells showed classical OERs of 2.4260.34
and 2.561.04, respectively while the basal cell line MDA-MB-231
had a slightly lower OER of 1.860.73 (Figs. 3 and 4C). This
confirmed that we indeed irradiated under hypoxic conditions.
However, survival curves for the claudin-low SUM159PT cell line
not only revealed the highly radioresistant phenotype of this cell
line (Figs. 2, 4A and 4B) but also suggested that radiation survival
of clonogenic cells from this cell line did not differ under hypoxic
and normoxic conditions (OER=1.160.26) (Figs. 2 and 4C). This
suggested a negative correlation of the OER and increasing
malignancy of the breast cancer subtype the cell lines were
originally derived from.
Next we tested if similar results could be obtained using patient-
derived material (BCCL2 and BCCL3). Cells from both samples
were highly resistant to radiation (Figs. 2, 4A and 4B) and like in
SUM159PT cells, we found only small differences between the
survival curves of hypoxic and normoxic cells (BCCL2:
OER=1.160.32; BCCL3: OER=1.360.24) (Figs. 2 and 4C).
Figure 2. Radiation response of differentiated cells. Clonogenic survival assays of established breast cancer cells lines and primary patient-
derived breast cancer samples under normoxic and hypoxic conditions. Data was fitted using a linear quadratic model.
doi:10.1371/journal.pone.0034545.g002
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Breast cancer cell lines and clinical breast cancer samples
contain varying numbers of cells that exhibit a cancer stem cell
phenotype [16,17] and by definition clonogenic survival assays
only test for the survival of cells capable of going through at least
5–6 replication cycles, thus measuring the combined survival of
cells with short- and long-term proliferative capacity. Sphere-
forming assays correlate with self-renewal capacity and tumorige-
nicity and are as such a better tool to estimate the number of CSCs
in a tumor cell population [16]. Mammosphere assays are
performed in the absence of fetal calf serum and in the presence
of EGF and bFGF [18]. Under these conditions, differentiated
cells die from anoikis while BCSCs form mammospheres from
single cells if seeded at clonal densities [19]. In order to assess the
OER of BCSCs more directly we repeated the above radiation
experiment. Instead of performing clonogenic survival assays we
seeded the cells into mammosphere media in ultra-low adhesion
plate and measured the number of sphere-forming cells after
exposure to radiation under normoxic and hypoxic conditions.
When cultured as mammospheres, all cells except MCF-7 cells
were remarkably radioresistant (Fig. 3). However, the survival
curves obtained from experiments performed under hypoxic and
normoxic conditions for each individual cell line and for cells from
patient samples did not differ and showed an OER close to 1
(Fig. 4C).
Expression of free radical scavengers and oxygen
enhancement ratio in BCSCs
In order to study which part of the free radical detoxification
system was upregulated in BCSCs, we performed quantitative RT-
PCR for the Foxo family of transcription factors (Foxo1, 3, and 4),
key enzymes of the glutathione system (GSS, GCLM, GPX-1),
SOD1 and SOD2, the thioredoxin system (TMX1-4) and catalase.
In general, more aggressive breast cancers (MDA-MB-231,
SUM159PT, BCCL2, BCCL3) had lower levels of TMX1 and
SOD1 relative to the luminal MCF-7 cells, and showed up-
regulated expression of TMX3, Foxo1, GSS and SOD2 (Fig. 5).
However, this picture was not strictly uniform, indicating that
Figure 3. Radiation response of BCSCs. Mammosphere assay using the same cells as in Figure 2. Data was fitted using a linear quadratic model.
doi:10.1371/journal.pone.0034545.g003
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systems.
When we related the expression levels of the above genes to
OER values and the surviving fraction at 8 Gy (SF8Gy) we found
that low expression levels of SOD1/Cu-ZnSOD (Pearson’s
correlation, p=0.005) and high expression levels of SOD2/
MnSOD (p=0.03) were correlated with a low OER (Fig. 6). A
high SF8Gy under normoxic conditions was correlated with low
expression levels of SOD1/Cu-ZnSOD (p=0.013), TMX1
(p=0.022) and high expression levels of SOD2/MnSOD
(p=0.024) (Fig. 7).
Discussion
The observation that hypoxia protects cancer cells from
radiation [20,21,22] and to an even greater extent from many
chemotherapeutic drugs [23] has led to decades of experimental
and clinical research aimed to improve treatment responses
through correction of tumor hypoxia. It is in general accepted that
modifying hypoxia improves loco-regional control after radiation
treatment. A recent meta-analysis studying 4805 patients with
HNSCC treated in 32 randomized clinical trials reported
improved loco-regional control (8%), disease-specific (7%) and
overall survival (3%) if tumor hypoxia was modified [24].
However, even though this report studied a very heterogeneous
group of trials that employed different radiation therapy
techniques and strategies to correct tumor hypoxia it is still
remarkable that the observed effects were rather moderate. In
contrary, differences in loco-regional control between anemic and
non-anemic patients with HNSCC, which were attributed to
tumor hypoxia, were substantial [25] but correction of tumor
anemia through neither blood transfusion [26] nor recombinant
erythropoietin [27] corrected the inferior treatment outcome of
anemic patients. In the light of an OER of 2–3 for most tumor
cells these results suggest that the correction of hypoxia in most of
these studies was suboptimal. An alterative interpretation would be
that some tumor cells exhibited an intrinsic radioresistance that
was independent of hypoxia and that is maintained when cells
were re-oxygenated. Our study suggests that in breast cancers such
an intrinsically radioresistant tumor cell population indeed exists
and that it overlaps with the putative BCSC population. This
population is not further protected by hypoxia from radiation
doses applied in clinical radiotherapy.
Consistent with our previous observation of reduced radiation-
induced free-radical formation in BCSCs [11], cell lines and
patients samples that had high numbers of BCSCs had high
expression levels of free radical scavenger mRNAs. The overex-
pression of SOD2/MnSOD, a mitochondria-specific SOD was of
particular interest as SOD2/MnSOD is known to protect cells
from radiation-induced apoptosis [28] and BCSC do not induce
apoptosis in response to radiation [14]. However, the scavenging
system used by BCSCs to protect from radiation is most likely not
restricted to SOD2/MnSOD and may vary between samples from
different patients and even within the different cells of a breast
tumor.
Figure 4. Surviving fractions at 8 Gy and OER. SF8Gy in clonogenic survival assays (A) and mammosphere assays (B) were calculated. (C)
Radiation doses required for 50% cell killing were calculated for normoxic and hypoxic conditions and expressed as ratios (hypoxic:normoxic; oxygen
enhancement ratio (OER)).
doi:10.1371/journal.pone.0034545.g004
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improved clinical outcome as dramatically as it affects cell survival
experimentally and it raises the question if and how hypoxia
contributes to decreased local control after radiation therapy.
Furthermore, the reasons for radioresistance are multifactorial, are
not restricted to tumor hypoxia alone, and are under modulation
by the microenvironment. One possible view is that tumor
hypoxia is largely a surrogate marker for more aggressive tumors.
However, given the multiple pathways affected by hypoxia this
view is rather an oversimplification [29] and even if hypoxia does
not affect CSC survival after exposure to ionizing radiation
directly, it may still contribute to CSC survival through
reprogramming of non-tumorigenic cancer cells into CSCs. Such
reprogramming has been described for CD133
2 non-tumorigenic
glioblastoma cells [30] and might be even enhanced during
radiotherapy [31] especially if differentiated cells in hypoxic areas
are protected from radiation. If this is indeed the case, tumor
hypoxia will remain an important factor in clinical oncology and
preventing reprogramming of previously non-tumorigenic differ-
entiated cancer cells into CSCs could be an attractive new target
in cancer therapy.
Materials and Methods
Cell lines
Human SUM159PT breast cancer cell lines were purchased
from Asterand (Asterand, Inc., MI). Human MCF-7, T47D, and
MDA-MB-231 breast cancer cell lines were purchased from
American Type Culture Collection (Manassas, VA). SUM159PT
cells were cultured in log-growth phase in F12 Medium
(Invitrogen, Carlsbad, CA) supplemented with 5% fetal bovine
serum (Sigma Aldrich, St Louis, MO), penicillin (100 units/ml)
and streptomycin (100 mg/ml) (both Invitrogen), and insulin
(5 mg/mL) and hydrocortisone (1 mg/ml). MCF-7, T47D, and
MDA-MB-231 cells were cultured in log-growth phase in
Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen,
Carlsbad, CA) supplemented with 10% fetal bovine serum,
penicillin and streptomycin. All cells were grown in a humidified
Figure 5. Expression of free radical scavenger mRNAs in breast cancer cells. qRT-PCR using primers for 13 mRNAs involved in free radical
scavenging. Expression levels are expressed relative to expression levels found in MCF-7 cells.
doi:10.1371/journal.pone.0034545.g005
OER of Breast Cancer Stem Cells
PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e34545incubator at 37uC with 5% CO2. All cell lines were engineered to
express a fusion protein between the green fluorescent protein
ZsGreen and the C-terminal degron of murine ornithine
decarboxylase as previously described [13].
Primary Human Breast Cancer Specimens
Anonymized primary tumor specimens were received from the
Translational Pathology Core Laboratory (TCPL) and obtained
under a protocol approved by the University of California, Los
Angeles Institutional Review Boards (IRB#11-002504). BCCL2 is
an invasive ductal carcinoma, grade 3, pT2, N0, Mx,E R +,P R 2,
HER/Neu3+. BCCL3 is an extensive ductal carcinoma in situ
(90%), Invasive ductal carcinoma (10%), grade 1, pT1b, N0 (i-)(sn),
Mx,E R 2,P R 2, HER/Neu2. Both patients were previously
treated for breast cancer of the contralateral breast.
Flow cytometry
BCSCs were identified based on their low proteasome activity
[13,14] using the ZsGreen-cODC reporter system. Cells were
trypsinized and ZsGreen-cODC expression was assessed by flow
cytometry (Miltenyi Biotech Inc., Auburn, CA) and the FlowJo
software package (Tree Star Inc., Ashland, OR. Version 9.3.1).
Cells were defined as ‘‘ZsGreen-cODC positive’’ if the fluores-
cence in the FL-1H channel exceeded the fluorescence level of
99.9% of the empty vector-transfected control cells.
Aldefluor Assay
The ALDEFLUOR kit (StemCell Technologies, Durham, NC,
USA) was used to assess the size of the population with ALDH1
enzymatic activity. Cells were suspended in ALDEFLUOR assay
buffer containing ALDH1 substrate (BAAA, 1 mmol/l per 1610
6
cells) and incubated for 40 minutes at 37uC. For negative controls
an aliquot of each sample of cells was treated with 50 mmol/L
diethylaminobenzaldehyde (DEAB), a specific ALDH1 inhibitor.
The gates used to identify ALDH1
+ cells were established using
ALDEFLUOR-stained cells treated with DEAB as negative
controls. Samples were analyzed using MACSQuant Analyzer
flow cytometer and the FlowJo software package.
Irradiation
Cells grown as monolayers were irradiated at room temperature
while inside a hypoxic chamber (Coy Laboratory Products, Grass
Figure 6. Correlation of free radical scavengers and OER. Correlation of free radical scavenger mRNA expression and oxygen enhancement
ratios found in breast cancer cell lines and patient samples.
doi:10.1371/journal.pone.0034545.g006
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60Co irradiator (Theratronics T-1000) in 95%
N2/5% CO2 or 95% air/5% CO2 at a dose rate of 0.49 Gy/min
for the time required to apply a prescribed dose. Corresponding
controls were sham irradiated.
Clonogenic Survival Assays
For clonogenic survival assays, cells were irradiated, trypsinized,
counted, and plated into 10 cm Petri dishes using standard culture
media. Three weeks later, cells were fixed with 70% ethanol,
stained with crystal violet and colonies containing more that 50
cells were counted and normalized to their corresponding un-
irradiated control. Data points were fitted using a linear-quadratic
model (GraphPad Prism, version 5.0).
Mammosphere Assay
After irradiation, cells were trypsinized, counted, and plated
into mammosphere media (DMEM-F12, 0.4% BSA (Sigma),
10 ml/500 ml B27 (Invitrogen) 5 mg/ml bovine insulin (Sigma),
4 mg/ml heparin (Sigma), 20 ng/ml fibroblast growth factor 2
(bFGF, Sigma) and 20 ng/ml epidermal growth factor (EGF,
Sigma)) into 96-well ultra-low adhesion plates. For 0 Gy controls,
256 cells/well were seeded and diluted 1:1 over the entire plate.
For plates subjected to irradiation, the number of cells seeded was
adjusted based on their radiation sensitivity. Growth factors, EGF
and bFGF, were added every 3 days, and the cells were allowed to
form spheres for 20 days. The number of spheres formed per well
was then counted manually with a cut-off diameter of 100 mm and
expressed as a percentage of the initial number of cells plated. To
avoid counting spheres that resulted rather from clumping than
from a single clonal cell, only sphere counts within the linear part
of the dilution curves were taken into consideration. Three
independent experiments were performed.
Quantitative Reverse Transcription-PCR
Total RNA was isolated using TRIZOL Reagent (Invitrogen).
cDNA synthesis was carried out using the SuperScript Reverse
Transcription III (Invitrogen). Quantitative PCR was performed
in the My iQ thermal cycler (Bio-Rad, Hercules, CA) using the 26
iQ SYBR Green Supermix (Bio-Rad). Ct for each gene was
determined after normalization to GAPDH or RPLP0 and DDCt
was calculated relative to the designated reference sample. Gene
expression values were then set equal to 2
2DDCt as described by
Figure 7. Correlation of free radical scavengers and SF8Gy. Correlation of free radical scavenger mRNA expression and SF8Gy found in breast
cancer cell lines and patient samples.
doi:10.1371/journal.pone.0034545.g007
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were synthesized by Invitrogen.
Statistics
Unless indicated otherwise, at least three biological independent
experiments were performed. A p-value equal to or less than 0.05
was considered to indicate a statistical significant difference. All
data is represented as mean 6 standard deviation.
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